Maze Therapeutics, Inc. Common Stock (MAZE) - Total Assets
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) holds total assets worth $422.06 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MAZE book value for net asset value and shareholders' equity analysis.
Maze Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Maze Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Maze Therapeutics, Inc. Common Stock's total assets of $422.06 Million consist of 83.8% current assets and 16.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MAZE market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maze Therapeutics, Inc. Common Stock's current assets represent 83.8% of total assets in 2024, an increase from 70.8% in 2022.
- Cash Position: Cash and equivalents constituted 81.8% of total assets in 2024, up from 66.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Maze Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Maze Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Maze Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.70 | 8.77 | 2.09 |
| Quick Ratio | 17.70 | 8.77 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $369.19 Million | $136.40 Million | $17.79 Million |
Maze Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Maze Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.83 |
| Latest Market Cap to Assets Ratio | 5.39 |
| Asset Growth Rate (YoY) | 236.4% |
| Total Assets | $240.54 Million |
| Market Capitalization | $1.30 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Maze Therapeutics, Inc. Common Stock's assets at a significant premium (5.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Maze Therapeutics, Inc. Common Stock's assets grew by 236.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Maze Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Maze Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $240.54 Million | +236.40% |
| 2023-12-31 | $71.50 Million | -52.32% |
| 2022-12-31 | $149.96 Million | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidn… Read more